{"id":"bec2-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEC2 is a murine monoclonal antibody-based vaccine designed to induce an anti-idiotypic immune response that mimics the GD3 ganglioside, a tumor-associated antigen found on melanoma and small cell lung cancer cells. By vaccinating patients with BEC2, the immune system is trained to recognize and attack cancer cells expressing GD3. This approach aims to generate both cellular and humoral immunity against the tumor antigen.","oneSentence":"BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:10.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer (SCLC)"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT00006352","phase":"PHASE3","title":"Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1999-09","conditions":"Lung Cancer","enrollment":453},{"nctId":"NCT00003279","phase":"PHASE3","title":"Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-03","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT00037713","phase":"PHASE3","title":"Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"1998-09","conditions":"Carcinoma, Small Cell Lung","enrollment":515}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEC2 Vaccine","genericName":"BEC2 Vaccine","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Biologic","firstApprovalDate":"","aiSummary":"BEC2 is a therapeutic cancer vaccine that targets the GD3 ganglioside antigen expressed on tumor cells to stimulate an immune response against cancer. Used for Small cell lung cancer (SCLC), Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}